This HTML5 document contains 68 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n23http://linked.opendata.cz/resource/drugbank/drug/DB01288/identifier/chemspider/
dctermshttp://purl.org/dc/terms/
n26http://linked.opendata.cz/resource/drugbank/drug/DB01288/identifier/chebi/
n22http://linked.opendata.cz/resource/AHFS/
n13http://linked.opendata.cz/resource/mesh/concept/
n4http://linked.opendata.cz/resource/drugbank/dosage/
n16http://linked.opendata.cz/resource/drugbank/mixture/
n20http://linked.opendata.cz/resource/drugbank/drug/DB01288/identifier/pharmgkb/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01288/identifier/wikipedia/
n9http://bio2rdf.org/drugbank:
n25http://linked.opendata.cz/resource/drugbank/drug/DB01288/identifier/bindingdb/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01288/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n18http://linked.opendata.cz/resource/drugbank/drug/DB01288/identifier/pubchem-substance/
n11http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n12http://linked.opendata.cz/ontology/mesh/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01288/identifier/iuphar/
n24http://linked.opendata.cz/resource/drugbank/drug/DB01288/identifier/drugbank/
n3http://linked.opendata.cz/ontology/drugbank/
n21http://linked.opendata.cz/resource/drugbank/drug/DB01288/identifier/guide-to-pharmacology/
n5http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n7http://linked.opendata.cz/resource/atc/
n6http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01288
rdf:type
n3:Drug
n3:description
An adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic. [PubChem]
n3:dosage
n4:271B6309-363D-11E5-9242-09173F13E4C5 n4:271B630A-363D-11E5-9242-09173F13E4C5 n4:271B630B-363D-11E5-9242-09173F13E4C5 n4:271B630C-363D-11E5-9242-09173F13E4C5 n4:271B630D-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:indication
Fenoterol is used for the treatment of asthma.
owl:sameAs
n9:DB01288 n11:DB01288
dcterms:title
Fenoterol
adms:identifier
n15:Fenoterol n17:3343 n18:46509099 n19:557 n20:PA10079 n21:557 n23:3226 n24:DB01288 n25:50131281 n26:149226
n3:mechanismOfAction
Beta(2)-receptor stimulation in the lung causes relaxation of bronchial smooth muscle, bronchodilation, and increased bronchial airflow.
n3:synonym
Fenoterolum 5-{1-hydroxy-2-[2-(4-hydroxy-phenyl)-1-methyl-ethylamino]-ethyl}-benzene-1,3-diol 1-(P-Hydroxyphenyl)-2-((beta-hydroxy-beta-(3',5'-dihydroxyphenyl))ethyl)aminopropane 1-(3,5-Dihydroxyphenyl)-1-hydroxy-2-((4-hydroxyphenyl)isopropylamino)ethane 3,5-Dihydroxy-alpha-(((P-hydroxy-alpha-methylphenethyl)amino)methyl)benzyl alcohol Phenoterol
n3:toxicity
Symptoms of overdose include angina (chest pain), dizziness, dry mouth, fatigue, flu-like symptoms, headache, heart irregularities, high or low blood pressure, high blood sugar, insomnia, muscle cramps, nausea, nervousness, rapid heartbeat, seizures, and tremor.
n6:hasAHFSCode
n22:12-12-08-12
n3:foodInteraction
Take without regard to meals.
n3:mixture
n16:271B6308-363D-11E5-9242-09173F13E4C5
n3:synthesisReference
Zeile, K., Thoma, O. and Mentrup, A,; U.S. Patent 3,341,593; September 12, 1967; assigned to Boehringer lngelheim GmbH, Germany.
n12:hasConcept
n13:M0008335
n3:IUPAC-Name
n5:271B6312-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B6318-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B6317-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B6314-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B6315-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B6316-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B6310-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B630E-363D-11E5-9242-09173F13E4C5 n5:271B6311-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B630F-363D-11E5-9242-09173F13E4C5
n6:hasATCCode
n7:G02CA03 n7:R03CC04 n7:R03AC04
n3:H-Bond-Acceptor-Count
n5:271B631E-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B631F-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B6319-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B631A-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B631C-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B631B-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B631D-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
13392-18-2
n3:category
n3:Bioavailability
n5:271B6324-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B6326-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B6327-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n5:271B6328-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B6323-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B6322-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B6325-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B6313-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B6320-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B6321-363D-11E5-9242-09173F13E4C5